Mayne Pharma traded at 0.26 this Monday July 4th, decreasing 0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Mayne Pharma lost 8.77 percent. Over the last 12 months, its price fell by 20.00 percent. Looking ahead, we forecast Mayne Pharma to be priced at 0.25 by the end of this quarter and at 0.24 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.26
Daily Change
0%
Yearly
-20.00%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Avita Therapeutics Inc 1.48 0.04 2.43% -72.22%
Ansell 22.47 0.33 1.49% -45.57%
Cochlear 199.29 -0.34 -0.17% -17.81%
CSL 274.80 5.57 2.07% -2.55%
Ecofibre Ltd 0.21 0 0% -74.39%
Healius Ltd 3.73 0.08 2.19% -19.61%
Integral Diagnostics Ltd 3.05 0.05 1.67% -41.35%
Medical Developments International Ltd 1.74 0.13 8.07% -61.50%
Nanosonics Ltd 3.57 0.14 4.08% -36.36%
Next Science Ltd 0.85 0.06 7.59% -47.53%
Probiotec Ltd 2.21 -0.02 -0.90% 6.76%
Polynovo Ltd 1.34 0.03 2.30% -49.24%
Ramsay Health Care 72.67 -0.33 -0.45% 15.22%
ResMed 31.34 0.84 2.75% -4.89%
Sonic Healthcare 33.37 0.43 1.31% -11.81%
Sigma Healthcare Ltd 0.58 -0.01 -1.69% -4.13%
Telix Pharmaceuticals Ltd 4.74 0.10 2.16% -17.28%

Indexes Price Day Year
AUALL 6797 76.50 1.14% -10.44%

Mayne Pharma
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.